$ query --field faq
PT-141: Direct Answers, Read Off the Record
Plain, sourced answers to the questions people actually ask — with the approval boundary kept in view.
What is PT-141?
PT-141 is a synthetic cyclic heptapeptide and a melanocortin receptor agonist — it switches on MC3R/MC4R receptors that sit mostly in the brain [1]. Its generic name is bremelanotide. In animals, systemic doses produced erections and activated hypothalamic neurons; in men with erectile dysfunction it produced dose-dependent erectile activity [1]. It is FDA-approved only for HSDD in premenopausal women [7].
What is PT-141 peptide?
The PT-141 peptide is a ring of seven amino acids modeled on alpha-MSH, the body's natural melanocortin signal. Its cyclic structure makes it more stable than a linear peptide [1]. It acts centrally on melanocortin receptors rather than on blood vessels [1]. Sold as a pharmaceutical it is bremelanotide; sold as a "research chemical" it is unregulated material of unverified purity.
What does the PT-141 peptide do?
PT-141 activates central melanocortin receptors (MC3R/MC4R) in brain circuits tied to sexual desire and arousal [1]. In the pivotal trials it increased sexual desire and reduced desire-related distress in premenopausal women with HSDD [3]. A brain-imaging study showed it changes how the brain processes sexual cues for up to 24 hours [5]. It does not act on blood flow.
What is PT-141 used for?
PT-141 (bremelanotide) is FDA-approved for one use: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, as a 1.75 mg subcutaneous as-needed injection [7]. Other uses people ask about — for men, for erectile dysfunction, for postmenopausal women, or for performance — are off-label or unapproved, even where early studies exist [1].
Is PT-141 the same as bremelanotide?
Yes. PT-141 and bremelanotide are two names for the same molecule. Bremelanotide is the international nonproprietary name (INN); PT-141 is the older research code [10]. It is a melanocortin receptor agonist approved in June 2019 for HSDD in premenopausal women [10]. The approved pharmaceutical and unregulated "research chemical" material share the name but not the oversight.
What is bremelanotide?
Bremelanotide is the generic (INN) name for PT-141, a melanocortin (MC3R/MC4R) receptor agonist [10]. It received its first regulatory approval in the United States in June 2019 for HSDD in premenopausal women, given as a 1.75 mg subcutaneous as-needed injection [10]. It works centrally in the brain, not on vascular blood flow [1].
What are the benefits of PT-141?
In premenopausal women with HSDD, the Phase 3 RECONNECT trials found bremelanotide modestly but significantly improved sexual desire (FSFI-desire +0.35) and reduced desire-related distress (FSDS-DAO item 13 -0.33) versus placebo [3]. A 52-week extension found the gains were sustained [4]. Independent re-analyses argue the effect is statistically real but small. Benefits outside this approved group are not established.
How does PT-141 work?
PT-141 activates melanocortin receptors, chiefly MC4R, in hypothalamic and limbic brain circuits that govern sexual desire — engaging dopamine-using pathways tied to arousal [1]. Unlike PDE-5 inhibitors, which act on vascular smooth muscle, it works centrally on the neural circuitry of motivation [1]. An fMRI study showed it alters brain processing of sexual cues for up to 24 hours [5].
What receptors does PT-141 act on?
PT-141 acts mainly on the melanocortin 4 receptor (MC4R), with a secondary action at the melanocortin 3 receptor (MC3R) [1]. Both are central-nervous-system members of the five-receptor melanocortin family and are concentrated in the hypothalamus and limbic system [1]. Activation of MC1R in the skin explains the hyperpigmentation seen with repeated frequent dosing [1].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts centrally on melanocortin receptors in hypothalamic circuits of sexual motivation, not on the blood vessels [1]. This is the key difference from PDE-5 inhibitors, which act peripherally on vascular smooth muscle to improve erectile blood flow [1]. A human fMRI study confirmed it changes central brain processing of sexual cues [5].
What is a melanocortin receptor agonist?
A melanocortin receptor agonist is a molecule that activates the melanocortin receptors — a family of five G-protein-coupled receptors (MC1R-MC5R) that respond to signals like alpha-MSH. PT-141 is one, acting chiefly at the central MC4R and MC3R subtypes [1]. "Agonist" means it switches the receptor on, the way the body's own alpha-MSH would [1].
Does PT-141 increase testosterone?
No. A common misconception is that PT-141 raises testosterone; it does not act through the HPG axis (the hormone loop that controls testosterone) and does not directly increase it [1]. Its mechanism is central melanocortin-receptor activation in the brain, separate from sex-hormone production [1]. It is also not a PDE-5 inhibitor and does not act on blood vessels [1].
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors act peripherally on vascular smooth muscle to improve erectile blood flow. PT-141 acts centrally, on melanocortin receptors in brain circuits of sexual desire and arousal [1]. The targets are entirely different: one is plumbing, the other is the neural signal for desire itself [1]. PT-141 is approved for female HSDD, not for erectile dysfunction [7].
What is the PT-141 dosage?
The only PT-141 dosage with regulatory standing is the approved bremelanotide label: 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated activity, no more than one dose per 24 hours and eight per month, for HSDD in premenopausal women [7]. The terminal half-life is about 2.7 hours [7]. This is the label figure, not a personal recommendation.
How much PT-141 should I take?
This site reports doses, it does not recommend them. The approved label dose for the approved indication is 1.75 mg subcutaneous as needed, capped at one dose per 24 hours and eight per month [7]. Any individual dosing decision belongs with a licensed clinician, not a website — and unregulated "research chemical" material carries no verified concentration to dose from in the first place [7].
How much PT-141 to inject?
The approved bremelanotide label specifies 1.75 mg injected subcutaneously, as needed, for HSDD in premenopausal women [7]. That is the documented label amount, reported here as a fact, not as guidance for any person. Studied doses elsewhere differed by route and indication — for example up to 2.5 mg in a Phase 1 metabolic protocol — but only the 1.75 mg as-needed schedule is approved [7].
What is the PT-141 dosage for women?
The approved PT-141 dosage for women with HSDD is 1.75 mg subcutaneous as needed [7]. Phase 2 dose-finding in women also studied 0.75 and 1.25 mg before 1.75 mg was selected [3]. In female-rat models, PT-141 selectively increased desire-driven sexual behavior without affecting reflexive behavior or motor activity [2]. The approved schedule caps use at one dose per 24 hours and eight per month [7].
How do you reconstitute PT-141?
The approved bremelanotide product is supplied as a ready-to-use subcutaneous injection per its US prescribing information, which is the authoritative source for handling [7]. This site summarizes the label and the literature; it does not provide preparation or reconstitution instructions for any material, and unregulated "research chemical" PT-141 has no verified concentration or sterility standard to prepare from [7].
How do you take PT-141?
Per the approved label, bremelanotide is given as a 1.75 mg subcutaneous injection, as needed, at least 45 minutes before anticipated sexual activity, for HSDD in premenopausal women [7]. Use is capped at one dose per 24 hours and eight per month [7]. This is the documented route and schedule from the label, reported as fact, not as instruction for any individual.
How often can you take PT-141?
The approved label limits bremelanotide to no more than one dose per 24 hours and no more than eight doses per month [7]. In the 52-week open-label extension (684 women), no new safety signals emerged with as-needed use, and the most common adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Those caps are safety limits in the label.
What is the approved bremelanotide dose?
The approved bremelanotide dose is 1.75 mg subcutaneous, as needed, for acquired, generalized HSDD in premenopausal women [7]. In the two Phase 3 RECONNECT trials (1,267 women), this dose produced statistically significant gains in desire (FSFI-desire +0.35) and reductions in desire-related distress (FSDS-DAO item 13 -0.33) versus placebo over 24 weeks [3]. It is the only approved schedule.
How long does PT-141 last?
PT-141 does not last long in the bloodstream. After subcutaneous injection, the median time to peak level is roughly 0.5-1.0 hour and the terminal half-life is about 2.7 hours (range 1.9-4.0 hours) per the US label [7]. Blood levels rise within the first hour and fall substantially within several hours; the molecule clears mostly through the kidneys [7].